SCHEMBL7253626

SCHEMBL7253626

CC(N1CCC(O)C1)n1ncc2ccc(-c3ccsc3)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 2/20 0.39
▸ PIM2 Q9P1W9 1/20 0.39
▸ HTR7 P34969 1/20 0.37
▸ LRRK2 Q5S007 3/20 0.35
▸ HTR6 P50406 4/20 0.34
▸ DRD2 P14416 4/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ KDM5A P29375 1/20 0.32
▸ PTGER3 P43115 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ HRH4 Q9H3N8 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ DRD3 P35462 1/20 0.31
▸ EEF2K O00418 1/20 0.31
▸ DYRK3 O43781 1/20 0.31
▸ JAK2 O60674 1/20 0.31
▸ RPS6KA5 O75582 1/20 0.31
▸ PRKD3 O94806 1/20 0.31
▸ MAP4K4 O95819 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7252894 0.78 HTR1D (0.41) PIM1HTR7HTR6DRD2HTR1D
SCHEMBL7258112 0.74 PIM1 (0.47) PIM1PIM2HTR7LRRK2DRD2
SCHEMBL7252886 0.65 HTR7 (0.42) HTR7HTR6DRD2HTR1DHRH1
SCHEMBL7256498 0.63 EEF2K (0.46) PIM1HTR7HTR1DBACE1EEF2K
SCHEMBL7258567 0.63 BRD4 (0.39) PIM1PIM2HTR7HTR6DRD2
SCHEMBL7253624 0.63 BRD4 (0.42) PIM1HTR7HTR6DRD2HTR1D
SCHEMBL7253584 0.63 HTR1D (0.42) PIM1HTR7HTR6DRD2HTR1D
SCHEMBL7253656 0.62 HTR7 (0.57) HTR7DRD2HTR1DDRD3
SCHEMBL7253427 0.62 HTR7 (0.55) HTR7HTR1D
SCHEMBL7256617 0.62 BRD4 (0.39) PIM1HTR7DRD2HTR1DBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 — — US claimed
US-6635639-B2 Treatment or diagnosis of central nervous system conditions NPS ALLELIX CORP. (CA) 2003-10-21 — — US disclosed
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 — — US disclosed
US-6380242-B1 FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS NPS ALLELIX CORP. (CA) 2002-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine CNR1, CNR2, KCNH1 PIM1 4713/4885PIM2 4690/4885HTR7 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback